
    
      The study was planned as an observation of Polyoxidonium® administered in addition to Russian
      Ministry of Healthcare (MoH) guidance for standard COVID-19 treatment. Regimens have no
      limitations to the use of concomitant therapy. The aim of the study is to observe the safety
      and efficacy of Polyoxidonium®, lyophilizate for solution for injections, 12 mg in addition
      to complex treatment of hospitalized patients with COVID-19.
    
  